Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is a critical immune receptor expressed primarily on microglia in the central nervous system (CNS) that plays a pivotal role in regulating neuroinflammatory responses, microglial survival, and phagocytic function. Since the discovery that loss-of-function variants in the TREM2 gene significantly increase the risk of Alzheimer's disease (AD) approximately three- to fourfold, TREM2 has emerged as a central player in neurodegenerative disease pathogenesis [1](https://doi.org/10.1016/j.neuron.2014.05.004). This page provides a comprehensive analysis of TREM2 structure, signaling mechanisms, downstream molecular pathways, and therapeutic implications for neurodegenerative diseases. [@guerreiro2013a]
```mermaid
graph TD
LIG["Ligands<br/>ApoE, Abeta, Phospholipids"] -->|"bind"| TREM2["TREM2 Receptor"]
TREM2 -->|"associates with"| DAP12["DAP12 / TYROBP<br/>ITAM Adaptor"]
DAP12 -->|"recruits and activates"| SYK["SYK Kinase"]
SYK -->|"activates"| PI3K["PI3K / AKT<br/>Pathway"]
SYK -->|"activates"| PLCG["PLCgamma Pathway"]
SYK -->|"activates"| MAPK["MAPK / ERK<br/>Pathway"]
PI3K -->|"promotes"| SURV["Cell Survival<br/>and Proliferation"]
PI3K -->|"promotes"| PHAG["Phagocytosis<br/>and Debris Clearance"]
PLCG -->|"Ca2+ signaling"| LIPID["Lipid Metabolism<br/>and Myelin Processing"]
MAPK -->|"modulates"| CYTO["Cytokine Modulation<br/>Anti-inflammatory"]
Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is a critical immune receptor expressed primarily on microglia in the central nervous system (CNS) that plays a pivotal role in regulating neuroinflammatory responses, microglial survival, and phagocytic function. Since the discovery that loss-of-function variants in the TREM2 gene significantly increase the risk of Alzheimer's disease (AD) approximately three- to fourfold, TREM2 has emerged as a central player in neurodegenerative disease pathogenesis [1](https://doi.org/10.1016/j.neuron.2014.05.004). This page provides a comprehensive analysis of TREM2 structure, signaling mechanisms, downstream molecular pathways, and therapeutic implications for neurodegenerative diseases. [@guerreiro2013a]
The TREM2 gene is located on chromosome 6p21.1 in humans and encodes a type I transmembrane protein belonging to the immunoglobulin superfamily. The mature TREM2 protein consists of an extracellular domain (ectodomain) of approximately 200 amino acids, a short transmembrane region, and a cytoplasmic tail that lacks canonical signaling motifs [2](https://doi.org/10.1074/jbc.M110.171520). The extracellular domain contains a single V-type immunoglobulin-like fold that mediates ligand binding, while the transmembrane domain contains a positively charged lysine residue that facilitates association with the adaptor protein DAP12. [@coats2019]
Alternative splicing generates at least two isoforms of TREM2: a membrane-bound form and a soluble form (sTREM2) that is generated through proteolytic cleavage by ADAM10 and ADAM17 at a site located approximately 40 amino acids upstream of the transmembrane domain [3](https://doi.org/10.15252/emmm.201809846). Soluble TREM2 is detectable in cerebrospinal fluid (CSF) and is thought to function as a decoy receptor, potentially modulating microglial activity in a paracrine manner. [@wang2015a]
Within the CNS, TREM2 is predominantly expressed by microglia, particularly in regions susceptible to neurodegenerative pathology such as the hippocampus and cerebral cortex. TREM2 expression is dynamically regulated by the local microenvironment; acute brain injury and neurodegenerative pathology upregulate TREM2 expression, reflecting its role in microglial activation and response to CNS damage [4](https://doi.org/10.1016/j.jneuron.2018.06.012). Single-cell RNA sequencing studies have identified TREM2 as a defining marker of disease-associated microglia (DAM) or neurodegenerative microglia (NGN), a specialized microglial phenotype characterized by upregulated genes involved in phagocytosis, lipid metabolism, and lysosomal function [5](httpshttps://doi.org/10.1016/j.cell.2017.05.045). [@krasemann2017a]
Low-level TREM2 expression has also been reported on peripheral myeloid cells including monocytes and macrophages, where it participates in responses to bacterial lipopolysaccharide (LPS) and other pathogen-associated molecular patterns (PAMPs). However, the functional significance of TREM2 in peripheral immune cells remains less well-characterized than its CNS functions. [@krasemann2017b]
TREM2 recognizes a diverse array of ligands that are broadly categorized into endogenous CNS ligands and exogenous pathogen-derived ligands. The endogenous ligands include: [@guerreiro2013b]
The immunoglobulin-like ectodomain of TREM2 forms a shallow groove capable of accommodating lipid molecules and small hydrophobic structures. Structural studies have revealed that ligand binding induces conformational changes in the TREM2 ectodomain that promote clustering of the receptor on the microglial membrane, a prerequisite for efficient signal transduction through the DAP12 adaptor [8](https://doi.org/10.1074/jbc.M110.171520). [@wang2015b]
TREM2 transduces signals through the DNAX-activating protein of 12 kDa (DAP12), also known as TYROBP (TYRO protein tyrosine kinase-binding protein). DAP12 is a transmembrane adaptor protein that contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. The association between TREM2 and DAP12 is mediated through charged residues in their transmembrane domains: the positively charged lysine in the TREM2 transmembrane domain interacts with a corresponding negatively charged aspartate in the DAP12 transmembrane region [9](https://doi.org/10.1084/jem.20081150). [@ferrari2014]
Upon ligand binding, TREM2 clusters and recruits DAP12, leading to phosphorylation of the ITAM tyrosine residues by Src family kinases. Phosphorylated ITAMs then serve as docking sites for the Syk (spleen tyrosine kinase) family of kinases, initiating downstream signaling cascades. [@paloneva2002]
Activation of the TREM2-DAP12 complex triggers multiple downstream signaling pathways: [@deczkowska2018a]
One of the most well-characterized functions of TREM2 is its role in promoting phagocytosis of apoptotic cells, cellular debris, and pathological protein aggregates. TREM2-dependent phagocytosis is essential for maintenance of CNS homeostasis, as impaired TREM2 function leads to accumulation of cellular debris and exacerbation of neuropathology [13](https://doi.org/10.1016/j.neuron.2015.05.013). [@trem2023b]
The phagocytic function of TREM2 involves reorganization of the actin cytoskeleton through Syk-dependent signaling. TREM2 activates Rac1 and other Rho GTPases that regulate actin polymerization at the phagocytic cup. Additionally, TREM2 promotes phagosome maturation through recruitment of lysosomal fusion machinery. [@deczkowska2018b]
In the context of Alzheimer's disease, TREM2-mediated phagocytosis facilitates clearance of Aβ deposits. However, the efficiency of Aβ clearance is influenced by TREM2 variant status, with risk variants associated with reduced phagocytic capacity. [@trem2015]
TREM2 provides critical survival signals for microglia, particularly in environments characterized by chronic inflammation or metabolic stress. The PI3K/Akt pathway activated by TREM2 promotes expression of anti-apoptotic proteins including Bcl-2 and Bcl-xL, protecting microglia from apoptosis induced by trophic factor withdrawal or inflammatory insults [14](https://doi.org/10.1016/j.cell.2017.05.045). [@strem2014]
Microglial proliferation in response to brain injury or neurodegeneration is also TREM2-dependent. The ERK and PI3K/Akt pathways activated by TREM2 contribute to cell cycle progression and expansion of the microglial population at sites of pathology.
A crucial function of TREM2 in microglia is regulation of lipid metabolism. RNA sequencing studies have demonstrated that TREM2 is required for upregulation of genes involved in cholesterol efflux and lipid droplet formation [15](https://doi.org/10.1016/j.cell.2017.05.045). This function is particularly relevant given the high lipid content of myelin debris and the importance of lipid handling in microglial responses to demyelination.
TREM2 activates the liver X receptor (LXR) and ATP-binding cassette transporters (ABCA1, ABCG1), promoting cholesterol efflux from microglia. Impaired TREM2 function leads to intracellular lipid accumulation and foam cell formation, a phenotype observed in both mouse models and human AD brain tissue.
TREM2 signaling modulates the production of cytokines and other inflammatory mediators by microglia. The net effect of TREM2 on neuroinflammation is context-dependent and influenced by the nature of the stimulus and disease stage:
The R47H variant (rs75932628) in TREM2 was first associated with Alzheimer's disease risk in 2013, with subsequent studies confirming that this and other rare coding variants in TREM2 increase AD risk by approximately three- to fourfold [16](https://doi.org/10.1056/NEJMoa1211857). The magnitude of this risk increase is comparable to the APOE ε4 allele, making TREM2 one of the strongest genetic risk factors for AD identified to date.
Key TREM2 variants associated with AD include:
| Variant | Amino Acid Change | Risk Effect | Population Frequency |
|---------|------------------|-------------|----------------------|
| R47H | Arginine → Histidine at position 47 | ~3-4x increased AD risk | ~0.3% in European populations |
| R62H | Arginine → Histidine at position 62 | ~2x increased AD risk | ~0.5% in European populations |
| D87N | Aspartate → Asparagine at position 87 | ~2x increased AD risk | Rare |
| Y38X | Tyrosine → Stop at position 38 | Complete loss of function | Very rare |
Functional studies have revealed that risk variants impair multiple aspects of TREM2 function:
Beyond Alzheimer's disease, TREM2 variants have been implicated in:
The relationship between TREM2 and amyloid pathology is complex and bidirectional. TREM2-dependent microglial phagocytosis contributes to clearance of Aβ deposits, and AD-risk variants are associated with reduced Aβ clearance efficiency. However, human neuroimaging studies have produced mixed results regarding the impact of TREM2 variants on amyloid plaque burden, with some showing increased plaque density in risk variant carriers and others finding no significant difference [20](https://doi.org/10.1016/j.neuron.2018.06.012).
TREM2 appears to have a more pronounced effect on tau pathology than on amyloid deposition. In mouse models, TREM2 deficiency leads to increased tau phosphorylation and aggregation, suggesting that TREM2-mediated microglial responses are important for containing tau pathology. Human imaging studies have confirmed that TREM2 risk variants are associated with faster tau accumulation and spread in the brain [21](https://doi.org/10.1016/j.jneuron.2018.06.012).
TREM2 plays a critical role in synaptic maintenance through clearance of synaptic debris and promotion of synaptic plasticity. TREM2 deficiency in mouse models leads to increased synaptic loss and cognitive impairment that precedes significant amyloid or tau pathology [22](https://doi.org/10.1016/j.neuron.2015.05.013).
Microglial TREM2 signaling supports cellular metabolism and bioenergetics, particularly under conditions of metabolic stress. TREM2 activation promotes glycolysis and mitochondrial function, while TREM2 deficiency leads to metabolic insufficiency and impaired microglial responsiveness.
Multiple companies have developed monoclonal antibodies targeting TREM2 to enhance its signaling function:
These antibodies are designed to bypass the need for ligand binding and directly activate TREM2 signaling pathways, potentially enhancing microglial function in AD patients.
Given that sTREM2 is generated through proteolytic cleavage and may have functional activity, strategies to modulate sTREM2 levels are being explored:
Gene therapy approaches to deliver TREM2 or enhance TREM2 expression are in early preclinical development. Viral vector-mediated delivery of TREM2 to microglia is technically challenging due to the difficulty of achieving microglial-specific targeting.
Small molecule TREM2 agonists represent an alternative to antibody-based approaches. Several companies have identified small molecules that enhance TREM2 signaling, though none have advanced to clinical trials as of early 2024.
Evidence for TREM2 involvement in Parkinson's disease (PD) is accumulating. TREM2 expression is increased in PD brain tissue, and genetic studies have identified TREM2 variants that modify PD risk [24](https://doi.org/10.1093/brain/awad112). The role of TREM2 in PD is likely related to clearance of alpha-synuclein aggregates and modulation of neuroinflammation.
In ALS, TREM2 is expressed by microglia and contributes to the inflammatory environment surrounding motor neurons. TREM2 variants modify disease progression, with some evidence suggesting that TREM2 deficiency accelerates disease onset while others indicate complex stage-dependent effects [25](https://doi.org/10.1093/brain/awad112).
TREM2 plays a protective role in demyelinating diseases by promoting clearance of myelin debris and supporting oligodendrocyte precursor cell differentiation. Multiple sclerosis patients show increased CSF sTREM2 levels during active disease, suggesting TREM2 activation is part of the regenerative response [26](https://doi.org/10.1093/brain/awad112).
Understanding TREM2 function has relied heavily on genetic mouse models. Trem2 knockout mice (Trem2^-/-) are viable and fertile, allowing comprehensive analysis of TREM2 deficiency in various disease contexts. These mice show impaired phagocytosis, reduced microglial survival, and altered inflammatory responses. Conditional knockout models have enabled cell-type-specific ablation of TREM2, distinguishing CNS-specific effects from potential peripheral contributions [27](https://doi.org/10.1016/j.jneuron.2018.06.012).
Transgenic mice expressing human TREM2 with AD-associated risk variants (R47H, R62H) have been generated to model the functional consequences of human risk alleles. These mice exhibit phenotypes intermediate between complete knockout and wild-type, providing insights into the partial loss-of-function mechanism of AD risk variants.
Several biochemical techniques have been instrumental in characterizing TREM2 signaling:
Advanced imaging technologies enable visualization of TREM2 function in living systems:
CSF sTREM2 has emerged as a biomarker of microglial activation in neurodegenerative diseases. ELISA-based quantification shows:
Multiple mouse models have been employed to study TREM2:
Primary microglial cultures and immortalized microglial cell lines (e.g., BV2, SIM-A9) enable detailed mechanistic studies:
Several key questions remain in TREM2 biology:
New frontiers in TREM2 research include:
TREM2 represents a critical node linking microglial immune surveillance to neurodegenerative disease pathogenesis. Its role in phagocytosis, cell survival, lipid metabolism, and inflammatory responses positions TREM2 as a master regulator of microglial function in the aging and diseased brain. The strong genetic association between TREM2 loss-of-function variants and Alzheimer's disease has catalyzed intensive research into TREM2 biology and therapeutic targeting.
Understanding the context-dependent effects of TREM2 signaling—from protective phagocytosis to potentially detrimental chronic inflammation—will be essential for developing effective TREM2-targeted therapies. Ongoing clinical trials of TREM2 agonists will provide critical insights into whether enhancing TREM2 function can slow or prevent neurodegeneration in human patients.
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate